Chundsell Medicals is a biotechnology startup established in 2007 as a spin off from Karolinska Institutet, Solna. The company is focused on bringing the research findings of Chunde Li and his team on prostate cancer genomics to the market. Their flagship product, the Prostatype® Test System, evaluates prostate cancer aggressiveness alongside current clinical parameters by analyzing the expression patterns of three specific prostate cancer embryonic stem cell genes in tumor cell tissue specimens.
With its last Venture Round investment at 01 January 2015 from Almi Invest and Creathor Ventures, Chundsell Medicals aims to disrupt the healthcare industry by providing healthcare professionals with a tool to predict disease outcome, overall survival, and cancer-specific survival of patients. The startup operates in the Biotechnology and Health Care industries, demonstrating a strong potential for growth and impact on the medical field.
